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Summary While non-invasive positive pressure ventilation (NIPPV) has become
an accepted management approach for patients with acute hypercapnia, it remains
unclear whether it can also be beneficial in stable chronic obstructive pulmonary
disease (COPD) patients with chronic respiratory failure. Randomised controlled trials
(RCT) with a maximum duration of 3 months showed contradictory effects in blood
gasses, dyspnoea, sleep efficiency and health-related quality of life. On the other
hand, several uncontrolled trials did show positive results in patients with
hypercapnia. Recently, an RCT compared the combination of NIPPV and long-term
oxygen treatment (LTOT) with LTOT alone for a period of 2 years in hypercapnic
patients. After this period dyspnoea decreased and health-related quality of life
improved in the NIPPV compared to the LTOT group. Reasons for the contradictory
results in the different trials are probably patient selection, adequacy of ventilation,
and length of ventilation. Therefore, at this moment there is no conclusive evidence
that NIPPV should be provided routinely to stable patients with COPD. However, a
selected group of patients might have clinical benefits from it. Patients who are
clearly hypercapnic, who can tolerate an effective level of ventilatory support, and
who get enough time to adjust to the ventilator might show clinical benefits even
after 3 months. A trial with ventilatory support in this group of patients can be
considered.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Chronic obstructive pulmonary disease (COPD) is
currently one of the leading causes of death in the
world and further increases in the prevalence are
predicted. Even with optimal medication, patients
with COPD often suffer from dyspnoea that limits
their exercise tolerance and impairs health-related
quality of life. Respiratory rehabilitation has shown
by a number of randomised controlled trials (RCTs)
that it improves dyspnoea, exercise tolerance and
health-related quality of life.1–4 Therefore, reha-
bilitation has become now part of the standard of
care for the more severely affected patients.
Newer approaches to the management of COPD
such as lung transplantation and lung volume
reduction surgery (LVRS)5 are probably only bene-
ficial in a selected group of patients.
While short-term non-invasive positive pressure
ventilation (NIPPV) has become an accepted man-
agement approach for patients with acute hyper-
capnia, it remains unclear whether it can also be
beneficial in stable COPD patients with chronic
respiratory failure. Two hypotheses for effective-
ness of NIPPV in stable patients with COPD have
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been discussed recently.6 The first one is that NIPPV
can be effective in resting the respiratory muscles.
Due to hyperinflation the diaphragm operates at a
disadvantageous position on its length–tension
curve. As shown by Bellamare and Grassino, a
number of factors all represented in the time
tension index (TTI) contribute to the development
of diaphragmatic fatigue.7 This index contains the
inspiratory load, represented by the pressure
generated by the diaphragm during each breath
(Pdi) as a proportion of maximal force generated by
the same muscle (Pdimax) multiplied by the duty
cycle represented by the inspiration time (Ti)
divided by the total time of the respiration (Ttot).
In formula TTI ¼ ðPdi=PdimaxTi=TtotÞ: If the TTI
exceeds 0.15, fatigue of the diaphragm may occur.
The theory behind NIPPV is that it alleviates fatigue
by improving inspiratory muscle capacity; however,
this has not been proven yet. The second hypoth-
esis contains the sleep theory. Many investigators
have shown that sleep quality is poor in patients
with severe COPD. In addition, they have fre-
quently desaturations together with periods of
hypoventilation. NIPPV may reduce the number of
arousals and so improving sleep quality. In addition
NIPPV may prevent worsening of nocturnal hypo-
ventilation, thereby possibly resetting the respira-
tory centre for CO2. Finally, this will lead to an
improved daytime ventilation.
This paper will review the papers that have been
published investigating the effects of NIPPV in
stable patients with COPD classified by the design
of the study, i.e. controlled and uncontrolled. The
different outcomes of these studies will be dis-
cussed leading to a conclusion where we stand
now with regard to NIPPV in stable patients with
COPD.
Randomised controlled trials
RCTs were identified from several sources, like
Medline, Embase, and Cumulated Index to Nursing
and Allied Health (CINAHL). In addition, records
were identified through hand searching of abstracts
from meetings of the American Thoracic Society,
the American College of Chest Physicians, and the
European Respiratory Society. We included in this
review both nocturnal NIPPV as well as daytime
NIPPV if they have been published as a full paper.
Patients in the treated group by NIPPV continued to
receive their usual management for COPD. The
control group received the same management as
the study group with the exception of their not
receiving NIPPV.
Short-term NIPPV
Until now five RCTs with a maximum duration of 3
months have been published as a full paper.8–12
Details of the studies are presented in Table 1.
Strumpf et al. published the first study in 1991 and
except for neuro-psychological function no signifi-
cant changes were detected.11 The reason for this
result might be due to the fact that only 7 out of
the 19 patients completed it, which under-powers
the study. In addition, the patients were not
particularly hypercapnic, while some patients were
even normocapnic. Gay et al. assessed the effects
of NIPPV in hypercapnic patients and showed that
NIPPV did not lead to an improvement in clinical
parameters.10 Again, in this study, only a small
number of patients completed the study. In
contrast to the previous studies Lin et al. deter-
mined the effects of NIPPV after 2 weeks and found
only a positive effect of the combination of NIPPV
and oxygen on the nighttime oxygenation.8 The
reason for their negative result might be that some
patients need more than 2 weeks of acclimatisation
before they become comfortable and feel confident
with the ventilator during the night. Meecham
Jones was the only study that showed clear
evidence of clinical benefits for nocturnal NIPPV
in patients with COPD.9 After 3 months the
combination of NIPPV and oxygen was better than
oxygen alone for gas-exchange, sleep efficiency
and health status. Renston et al. investigated the
effects of daytime NIPPV (2 h a day for 5 con-
secutive days).12 Despite the fact that no signifi-
cant changes were found in gas-exchange, patients
in the Bi-level Positive Airway Pressure (BiPAP)
group showed both a significant decrease in level of
dyspnoea and an improvement in 6-min walking
distance (6-MWD). However, it does not become
clear from the paper if BiPAP is significantly better
than sham treatment. We did not include the study
of Diaz et al. in our overview of the RCTs as no full
paper had been published yet.13
Recently, a meta-analysis of individual data from
RCTs was carried out comparing NIPPV with
conventional management of patients with COPD
and stable respiratory failure. RCTs were identified
from several sources.14 Only studies investigating
nocturnal NIPPV via a nasal or facemask for at least
5 h each day for at least 3 weeks were included.
Patients in the actively treated group continued to
receive their usual management for COPD next to
NIPPV. The control group had to have received the
same management as the study group with the
exception that they did not receive NIPPV. We were
able to find 4 RCTs that fulfilled the above-
mentioned criteria (Table 2)9–11,15 Three months
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data of the study of Casanova were included as
well.15 The study of Lin was excluded because their
intervention period was 2 weeks,8 while the study
of Renston was excluded because of daytime
ventilation.12 The long-term study of Clini was not
included because it had not been published as a full
paper at the time we did our analysis.16 Table 2
shows that 3 months of NIPPV in patients with
stable COPD did not improve lung function, gas-
exchange, or sleep efficiency. The high upper limit
of the confidence interval for the 6-MWD suggests
that some people did improve their walking
distance, while, on the other hand, the wide
confidence interval suggests also that some might
have a deterioration in 6-MWD. Currently, it is not
possible to identify a patient who will improve his
6-MWD before putting them on NIPPV. Due to a
limited number of included patients in this meta-
analysis, a clear clinical direction regarding the
effects of NIPPV in COPD cannot be provided.
Long-term NIPPV
Casanova et al. were the first to set up a long-term
trial with a duration of 1 year.15 They randomised
52 patients to either NIPPV plus standard care or to
standard care alone. The level of BiPAP was modest
(IPAP 12–14 cmH2O) and its effect was not con-
trolled during the night. After 3 months the number
of hospital admissions was less (5% versus 15%), but
this benefit was not seen at 6 months. After 12
months there were no significant changes in arterial
blood gasses and respiratory muscle strength,
whilst there were modest improvements in dys-
pnoea and neuro-psychological function. Recently,
Clini et al. reported a prospective, randomised,
controlled trial comparing the combination of
NIPPV and long-term oxygen treatment (LTOT) with
LTOT alone for a period of 2 years.16 Only patients
with a PaCO246:6 kPa were included. One hundred
and twenty patients were considered, 90 were
randomised and 47 completed the study. The level
of NIPPV was modest (IPAP of 1473 cmH2O), but
they used the ventilator for a considerable number
of hours (972 h). Compared with the period before
the study, total hospital admissions increased by
27% in the LTOT group whilst it decreased by 45% in
the NIPPV group. ICU admissions decreased with
NIPPV by 75% and 20% in the LTOT group. However,
both outcomes were not significantly different
between groups. After 2 years dyspnoea decreased
and health-related quality of life improved in the
NIPPV compared to the LTOT group. The study of
Clini suggests that NIPPV could have beneficial
effects in patients with COPD; however, these
ARTICLE IN PRESS
Ta
b
le
1
R
an
d
o
m
is
e
d
co
n
tr
o
ll
e
d
tr
ia
ls
o
f
sh
o
rt
-t
e
rm
N
IP
P
V.
Tr
ia
l
N
u
m
b
e
r
o
f
p
at
ie
n
ts
(t
re
at
m
e
n
t/
co
n
tr
o
ls
)
FE
V
1
m
e
an
(r
an
ge
)
Pa
C
O
2
m
e
an
(r
an
ge
)
Le
n
gt
h
(m
o
n
th
s)
IP
A
P
/E
PA
P
O
u
tc
o
m
e
m
e
as
u
re
s
E
ff
e
ct
s
St
ru
m
p
f
e
t
al
.1
1
C
ro
ss
-o
ve
r
tr
ia
l
(e
n
ro
ll
e
d
:
19
,
co
m
p
le
te
d
:
7)
0.
54
(0
.4
6
–
0.
88
)
49
(3
5
–
67
)
3
15
/2
A
B
G
,
R
M
,
w
al
ki
n
g
te
st
,
d
ys
p
n
e
a,
P
FT
,
sl
e
e
p
st
u
d
y,
N
P
fu
n
ct
io
n
Si
gn
ifi
ca
n
t
e
ff
e
ct
s
fo
r
N
P
fu
n
ct
io
n
G
ay
e
t
al
.1
0
Pa
ra
ll
e
l-
gr
o
u
p
tr
ia
l
(r
an
d
o
m
is
e
d
:
7/
6,
co
m
p
le
te
d
:
4/
6)
0.
68
(0
.5
–
1.
1)
55
(4
5
–
89
)
3
10
/2
A
B
G
,
6-
M
W
D
,
d
ys
p
n
o
e
a,
P
FT
,
sl
e
e
p
st
u
d
y
N
o
si
gn
ifi
ca
n
t
e
ff
e
ct
s
M
e
e
ch
am
-J
o
n
e
s
e
t
al
.9
C
ro
ss
-o
ve
r
tr
ia
l
(e
n
ro
ll
e
d
:
18
,
co
m
p
le
te
d
:
14
)
0.
86
(0
.3
3
–
1.
7)
56
(5
2
–
65
)
3
18
/2
A
B
G
,
6-
M
W
T,
H
R
Q
L,
P
FT
,
sl
e
e
p
st
u
d
y
Si
gn
ifi
ca
n
t
e
ff
e
ct
s
fo
r
A
B
G
,
sl
e
e
p
e
ffi
ci
e
n
cy
,
H
R
Q
L
Li
n
8
C
ro
ss
-o
ve
r
tr
ia
l
(e
n
ro
ll
e
d
:
12
,
co
m
p
le
te
d
:
12
)
33
%
p
re
d
.
51
(7
4)
2
(w
e
e
k)
12
/2
A
B
G
,
P
FT
,
R
V
E
L,
LV
E
F,
sl
e
e
p
st
u
d
y
Si
gn
ifi
ca
n
t
e
ff
e
ct
s
o
f
N
IP
P
V
an
d
O
2
o
n
n
o
ct
u
rn
al
o
xy
ge
n
at
io
n
R
e
n
st
o
n
1
2
Pa
ra
ll
e
l-
gr
o
u
p
tr
ia
l
(r
an
d
o
m
is
e
d
:
9/
8,
co
m
p
le
te
d
:
9/
8)
0.
75
(0
.4
5
–
1.
05
)
F
5
d
ay
s
fo
r
2
h
15
–
20
/2
A
B
G
,
E
M
G
,
R
M
,
6-
M
W
D
,
d
ys
p
n
o
e
a
Si
gn
ifi
ca
n
t
e
ff
e
ct
s
fo
r
d
ys
p
n
o
e
a
an
d
6-
M
W
D
1088 P.J. Wijkstra
improvements were not sufficiently large to advo-
cate the widespread use of NIPPV in these patients.
The long-term trial of Muir et al. was not included
in this systematic overview of RCTs as no full paper
had been published yet.17
Uncontrolled trials
In contrast to above-mentioned RCTs, most uncon-
trolled trials of NIPPV showed positive results.
Elliot et al. showed significant effects of nocturnal
NIPPV on gas-exchange in 8 patients with severe
COPD (mean FEV1 0.53 l) and hypercapnia (mean
PaCO2 8.0 kPa).
18 The change in decrease in PaCO2
was significantly correlated with a decrease in both
RV and gas trapping and with an increase in
ventilation. They did not find that the improve-
ments in gas-exchange were due to a relief of
muscle fatigue. Another study from this group,
including 12 patients, showed after 12 months of
NIPPV a significant decrease in PaCO2 and improved
sleep efficiency, while the quality of life was
unchanged.19 In contrast, Perrin et al. showed that
quality of life improved significantly by 6 months of
NIPPV. In this study, 14 patients with a mean PaCO2
of 7.8 kPa received volume ventilation during the
night.20 Beside an improved quality of life they also
reported significantly improved gas-exchange. The
same positive results were seen in the study of
Sivasothy.21 Twenty-six patients with severe COPD
(mean FEV1 0.7 l) and hypercapnia (PaCO2 8.6 kPa)
were ventilated by a volume ventilator during the
night. After 18 months (range 4–74) both gas-
exchange and quality of life improved significantly.
Another long-term study of Jones et al. showed
after 24 months of pressure ventilation significant
improvements in gas-exchange and reduction in
hospital admissions general practitioner visits.22 In
summary, these uncontrolled studies showed that
in a selected group of patients (with severe
hypercapnia) NIPPV can improve gas-exchange.
However, this does not lead to a concomitant
decrease in pulmonary artery pressure, as shown
recently.23 Despite these positive findings, we have
to be careful with its clinical implications, as these
studies did not include an adequate control group
who received otherwise the same medical manage-
ment.
Discussion
It is obvious that the studies we reviewed in this
paper do not present a clear picture as to whether
NIPPV in stable COPD is beneficial or not. In the
next section the rationale for NIPPV and issues that
might explain the differences in outcome will be
discussed.
Theoretical basis for NIPPV
There are some theoretical reasons why NIPPV
might be effective: (1) resetting the respiratory
centre to improve daytime gases, (2) resting
dysfunctional respiratory muscles thereby increas-
ing their daytime strength and endurance, (3)
improving peripheral muscle function from a better
milieu (pH, PaO2, PaCO2), and (4) preventing the
repeated nocturnal arousals thereby improving the
quality of sleep. In fact, only muscle rest and sleep
quality have been investigated in different studies.
Resting inspiratory muscles was the hypothesis
behind a major trial of negative pressure ventila-
tion (NPV). Shapiro et al. randomised 184 patients
with severe COPD to active or sham ventilation with
a poncho wrap negative pressure ventilator.24
There were no significant changes in respiratory
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Table 2 Primary results of a meta-analysis on nocturnal NIPPV.
Outcomes Contributing trials (referencesa) Sample size (NIPPV/control) Treatment effect
Mean 95% CI
FEV1
9,10,11,15 33/33 0.02 l 0.04, 0.09
FVC 9,10,11,15 33/33 0.01 l 0.14, 0.13
Pimax
10,11,15 24/24 6.2 cmH2O 0.2, 12.2
Pemax
10,11,15 24/24 18.4 cmH2O 11.8, 48.6
PaO2
9,10,11,15 33/33 0.0mmHg 3.8, 3.9
PaCO2
9,10,11,15 34/33 1.5mmHg 4.5, 1.5
6-min walk test 9,10 12/11 27.5m 26.8, 81.8
Sleep efficiency 9,10,11 13/11 4.0% 14.7, 6.7
aContributing trials: Meecham Jones et al.9, Gay et al.10; Strumpf et al.11; Casanova et al.15.
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muscle strength; however, whilst patients were
encouraged to use the ventilator for at least 5 h
each day, the average duration of use was closer to
3 h and the intensity of the treatment intervention
was quite variable. Celli25 and Zibrak26 also failed
to identify improvements in arterial blood gases or
respiratory muscle strength with NPV.
In contrast, studies that included patients with
higher PaCO2 levels showed improvements in
respiratory muscle function after NPV.27 One
uncontrolled study showed that NIPPV had induced
a significant decrease in PaCO2 in association with a
decrease of the pressure–time product of the
diaphragm. There also appeared to be a subgroup
of responders who had a significantly increased
trans-diaphragmatic pressure and were better
capable to clear CO2.
28 In addition, Belman et al.
showed that positive pressure ventilation was more
effective in unloading the diaphragm compared to
NPV.29 So, there is some evidence that NIPPV can be
effective in unloading the respiratory muscles;
however, this comes only from uncontrolled trials.
In contrast, none of the RCTs found a significant
improvement in respiratory muscle function.
Another theoretical explanation for the effects
of NIPPV is improved sleep efficiency. Five out of 7
RCTs did carry out a formal sleep study. Only
Meecham Jones, who measured the effectiveness
of ventilation in clearly hypercapnic patients,
showed an improved sleep efficiency.9 In an
uncontrolled very short-term trial of 3 days, Criner
et al. investigated gas-exchange and sleep effi-
ciency in patients with COPD.30 They compared
low-level continuous positive airway pressure with
BiPAP on 2 consecutive nights in patients with a
mean PaCO2 of 58(74)mmHg. No significant
changes were found in PaCO2, but there was a
significant improvement in sleep efficiency and
total sleep time.
In conclusion, there are currently no studies on
NPV or NIPPV that have provided evidence as to
whether the benefits they found in gas-exchange
were related to improvements in respiratory
muscle function or in sleep efficiency.
Selection of patients
Patients who are more hypercapnic seemed to have
more benefits from NIPPV. The RCTs from both
Meecham Jones9 and Clini16 both showed significant
benefits in different outcome parameters. In con-
trast to other RCTs, they did not include patients
with a PaCO2 under 6.6 kPa (see Tables 1 and 3). In
addition, Meecham Jones showed that the patients
who had an increase of PaCO2 during the night
before they were on NIPPV had the most benefit
in decreasing daytime PaCO2 after starting NIPPV
(Fig. 1). The other RCTs did include normocapnic
patients11,15 or patients who were mildly hyper-
capnic.7,9 The uncontrolled studies that included
only hypercapnic patients (lowest value of 6.3 kPa)
also had positive outcomes. In our meta-analysis we
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Table 3 RCTs of long-term nocturnal NIPPV.
Trial Type of trial
numbers patients
(treatment/
controls)
FEV1 mean
(range)
PaCO2
mean
(range)
Length
(months)
IPAP/EPAP Outcome
measures
Effects
Casanova
et al.15
Parallel-group trial
(randomized:
26/26, completed:
17/19)
0.85 (0.44–1.28) 51 (37–66) 12 12–14/4 ABG, RM, dyspnea,
PFT
Significant effect
for dyspnoea and NP
function
Clini16 Parallel-group trial
(randomised:
43/47, completed:
23/24)
0.70 (0.30–1.35) 55 (50–75) 24 14/2 ABG, RM, dyspnoea,
sleep study, HRQL,
hospitalisations
Significant long-
term effects for
dyspnoea and HRQL.
Positive trends for
hospital admissions
and ICU stay
Figure 1 Correlation between change in daytime
arterial PaCO2 and the change in mean overnight
transcutaneous PCO2 for individual patients (r ¼ 0:69;
p ¼ 0:01).
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expected heterogeneity between the four studies
based on different levels of PaCO2 at inclusion;
however, we could not detect such a difference,
probably because of the low number of patients
included in this analysis. Nevertheless, all available
studies do suggest that patients who are more
hypercapnic might benefit from NIPPV. In addition,
as published recently, it might be important to
identify unstable patients (X2 hospitalisations due
to respiratory failure in a 12-month period)
who might have benefited by chronic ventilatory
support.
Adequacy of ventilation
At this moment there is no evidence that pressure-
cycled ventilation is better or worse than volume
cycled. At the same time it is remarkable that all
RCTs using BiPAP showed both positive and negative
results, while the uncontrolled studies used mainly
volume-cycled ventilation and showed positive
effects. While there is no study comparing both
types in COPD patients only, Schonhofer et al. did
compare pressure-controlled ventilation with vo-
lume-controlled ventilation in patients with re-
spiratory failure.31 They concluded that the
majority of the patients who were initially satis-
factorily ventilated with a volume ventilator could
also adequately be ventilated with pressure venti-
lation. However, currently there is no evidence that
either type is preferable in patients with COPD.
Assist-control ventilation is frequently selected
as the mode of choice to enhance synchrony
between patient and ventilator. One study did use
time-cycled ventilation to reduce the level of
inspiratory muscle effort; however, asynchrony
between patient and machine was present in
20%.11 More important than the type of ventilation
might be the assessment as to whether the
ventilation was effective. Meecham Jones9 was
the only study that assessed the adequacy of
ventilation by transcutaneous PaCO2, while Strumpf
assessed it occasionally using end tidal CO2.
11 The
latter might easily miss hypoventilation, leading to
ineffective ventilation. In all other stu-
dies8,10,12,15,16 the effectiveness of ventilation
was not assessed, so a full evaluation of the
efficacy cannot be made. This means that we do
not know whether the inspiratory pressure that
were used were high enough. In the study of
Meecham Jones, mean inspiratory pressures of
18 cmH2O were used. These investigators probably
found that they needed these higher levels to
achieve effective ventilation. This might explain
why other studies, that did not assess their
ventilatory effectiveness, used lower pressures
and did not find beneficial effects of NIPPV. Finally,
since it takes time for the patient to get used to the
mask and for the clinician to find the appropriate
settings of the ventilator, it seems better to admit
the patients to the hospital. In this way, effective
ventilation can be achieved, as shown in the study
of Meecham Jones.9
Number of hours on NIPPV
Since it is not known what is the optimal duration of
ventilatory support, different approaches have
been used. There are two randomised controlled
studies12,13 treating patients with COPD for a short
period with ventilatory support during the day. In
one, the patients received BiPAP for 2 h daily for 5
days a week, while in the other BiPAP was given for
3 h daily, 5 days a week for 3 consecutive weeks.
These short periods produced significant benefits in
clinical parameters. However, without a parallel
improvement in gas-exchange it is difficult to
understand the underlying mechanism.12 At the
same time, 5 days seem to be a short time for the
patients to adjust to the machine. Still these two
studies showed that physiological improvements
could be assessed by very short-term periods of
ventilatory support. Other studies with positive
outcomes showed that a considerable number of
hours are effective. In the long-term trial of Clini
the mean number of hours on BiPAP was 972 h.16 In
the study of Meecham Jones the median number of
hours was 6.9 h (range 4.2–10.8).9 Until now there
is no study showing that more hours on ventilatory
support is better in reducing the work of breathing,
resting the respiratory muscles or improving sleep
quality. Probably because it is practical NIPPV has
been advocated to use it during the night as long as
possible.
Length of ventilation
The length of ventilatory support can also influence
the outcomes. Most studies were of relatively short
duration (3 months) and some of them could detect
significant clinical benefits after such a short
period. Two European studies followed the patients
for the longest period.16,17 Clini et al. showed an
improved quality of life after 2 years (Fig. 2) and an
improved dyspnoea already after 1 year.16 In
addition, they showed a reduction in both hospital
admissions and ICU admissions. Cumulative days
spent in hospital due to respiratory exacerbations
showed a trend in favour of those receiving NIPPV
(12.677.9 versus 16.9710.3), respectively. Muir
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compared 60 patients with severe COPD who
received LTOT and NIPPV with 62 patients who
received LTOT alone.17 After a median follow-up of
4.7 years there were no significant differences in
survival between the groups, with the exception of
patients older than 65 years in whom survival was
better in the NIPPVþ LTOT group. In contrast to
these long-term studies patients in the study of
Meecham Jones needed only 3 months to get
significant clinical benefits.9
Summary
In conclusion, there is currently no conclusive
evidence that NIPPV should be provided routinely
to stable patients with COPD. Still, a selected group
of patients might have clinical benefits from it.
Patients who are clearly hypercapnic, who can
tolerate an effective level ventilatory support, and
who get enough time to adjust to the ventilator
might show clinical benefits even after 3 months. A
trial with ventilatory support in this group of
patients can be considered.
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